BoomRay and Novartis Pharma sign $900m deal for radioligand therapy

PartnershipUndisclosed preclinical RLT assetPositive

AI Analysis

Summary

BoomRay Pharmaceuticals and Novartis Pharma have signed an exclusive worldwide licensing agreement for an undisclosed preclinical radioligand therapy asset valued at up to $900 million.

Importance:7/10

Sentiment:

0.60

partnershiplicensingradioligand therapypreclinicalexclusive worldwide license

Related Companies

$NVS

Read the original article

Published by Pharmaceutical Technology on September 23, 2026 9:18 AM

Read Original